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Abstract: The number of therapeutic antibodies in preclinical, clinical, or approved phases has been increasing exponentially, mostly
due to their known successes. Development of antibody engineering methods has substantially hastened the development of therapeutic
antibodies. A variety of protein engineering techniques can be applied to antibodies to improve their affinity and/or biophysical properties
such as solubility and stability. Antibody fragments (where all or some parts of constant regions are eliminated while the essential
antigen binding region is preserved) are more suitable for protein engineering techniques because there are many in vitro screening
technologies available for antibody fragments but not full-length antibodies. Improvement of biophysical characteristics is important
in the early development phase because most antibodies fail at the later stage of development and this leads to loss of resources and
time. Here, we review directed evolution and rational design methods to improve antibody properties. Recent developments in rational
design approaches and antibody display technologies, and especially phage display, which was recently awarded the 2018 Nobel Prize,
are discussed to be used in antibody research and development.
Key words: Antibody, antibody fragment, directed evolution, rational design, protein engineering, phage display, yeast surface display,
affinity, biophysical properties

1. Introduction
Hundreds of therapeutic antibodies and their derivatives
are being manufactured and tested in clinical trials.
Currently, there are more than 65 monoclonal antibodies
approved on the market for the treatment of various
diseases, mostly cancer. The rate of antibody therapeutics
receiving their first approvals has been increasing over
the last decade. Last year, 10 antibodies were approved in
either the European Union or the United States and this
number is expected to increase in the upcoming years
(Kaplon and Reichert, 2018).
The first technology that was used to produce
therapeutic antibodies was mouse hybridoma technology
(Frenzel et al., 2017). With this technology, therapeutic
monoclonal antibodies (mAbs) are obtained via the fusion
of murine B cells and myeloma cells. However, there are
some limitations in the use of these mAbs in humans,
especially the immune response against murine mAbs
(human antimouse antibody response) (Qin and Li,
2014). To overcome this problem, several approaches were

developed by utilizing recombinant DNA technology, such
as chimerization (replacement of the constant regions of the
murine antibodies with homologous human sequences),
which generally reduces the affinity and deteriorates
biophysical properties of mAbs. Therefore, it is essential
to apply affinity maturation and protein engineering
approaches after this process. More importantly, there are
known reproducibility problems related to the hybridoma
technique where sequence information is lost and features
of mAbs cannot be improved with many available in vitro
systems (Bradbury and Pluckthun, 2015).
Approximately 90% of approved antibody drugs are
full-length (IgG) and the rest are antibody fragments
(mostly Fab formats), where all or some parts of constant
regions are eliminated while the essential antigen binding
region is preserved. It is very well known that antibody
fragments usually show similar binding properties as their
full-length versions with even better biophysical properties
(Nelson, 2010). Compared to full-length antibodies,
antibody fragments have many advantages for therapeutic
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use: (i) lower immunogenicity due to lack of constant
regions, (ii) higher tumor penetration, (iii) cheaper and
larger scale production with bacteria, and (iv) availability
of various in vitro display technologies to improve several
characteristics of antibodies. Today, the number of
antibody fragments in clinical trials and on the market
is increasing faster than before due to their advantages.
Because most of the directed evolution approaches are only
available for antibody fragments, improvement of fulllength antibodies is usually conducted in their antibody
fragment format, and then those improved fragments are
converted back to full-length antibody format (Xiao et al.,
2017).
Protein engineering techniques such as directed
evolution and rational design approaches to discover
and/or improve antibodies are becoming more popular
both in the biopharmaceutical industry and research
environments. Applying these techniques in the early
discovery phase is important because it is high-throughput
and there is full control of protein sequence during the
development phase of biotherapeutics.
2. Antibody display technologies as directed evolution
approaches
For the past 40 years, hybridoma technology has been used
extensively to produce traditional monoclonal antibodies
for research and diagnostics. Recently, a number of
advanced methods called display technologies have
emerged as fast and high-throughput alternatives. Phage
display technology is the first radical in vitro approach
that allowed to produce human antibodies without any
need for immunization. In this technique, antibody
fragments are fused to a capsid protein of the phage and
thus expressed on the surface of the virus (García Merino,
2011; Chiu and Gilliland, 2016). Although phage display
is the most common antibody display technique, today
several recombinant display technologies are available
and basically classified in two categories: in vitro display
technologies (phage display, ribosome-mRNA display)
and in vivo display technologies (bacterial, yeast, and
mammalian cell-surface display) (Sergeeva et al., 2006;
Harel Inbar and Benhar, 2012; Brodel et al., 2018).
2.1. In vitro display technologies
2.1.1. Phage Display
The phage display technique was first discovered in 1985 by
George P Smith, who was one of three recipients of the 2018
Nobel Prize in chemistry for this discovery (Smith, 1985).
This was an important step to develop new approaches
for generation of mAbs. In this technique, a protein gene
is fused to a gene encoding a capsid protein of the virus
and the fused gene is inserted into a single-stranded DNA
of the phage (Karimi et al., 2016; Ledsgaard et al., 2018).
Basically, two types of capsid proteins are preferred; the
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first one is pIII that allows to fuse larger proteins and the
other one is pVIII. The most commonly used phages for
phage display are the filamentous ones (M13, Fd, and f1),
which are in the Ff family and have the ability to infect
only the strains of Escherichia coli containing F conjugative
plasmids (Li and Caberoy, 2010; Loset and Sandlie, 2012;
Karimi et al., 2016; Gustafson et al., 2018; Kiguchi et
al., 2018; Ledsgaard et al., 2018; Teixeira and GonzalezPajuelo, 2018).
Two different application systems have been developed
for phage display. In the first system, a protein sequence is
used as an insert and is fused to a capsid gene of the virus.
With this system, the desired protein is expressed within
the genome of the virus. In the other more preferred
system, a different plasmid called a phagemid is used and
the expression of the desired protein is separated from
the phage replication. Phagemids also include replication
origins of E. coli and a phage, a specific selection marker,
and specific tags that help detection and purification of the
desired protein (Li and Caberoy, 2010; Loset and Sandlie,
2012; Teixeira and Gonzalez-Pajuelo, 2018).
The phage display technique was first applied for
the variable fragments of antibodies and many different
antibody fragment formats have been displayed by this
technique. The antibody fragments that are displayed by
this technique are usually scFv (a single-chain variable
fragment) or Fab (antigen-binding fragment), and
nowadays the most popular ones are VH (nanobody, heavy
variable domain of the antibody) (Teixeira and GonzalezPajuelo, 2018). It is easy to convert these fragments to
full-length antibodies by recombinant DNA technology, if
needed.
The phage display technique is carried out by a process
of in vitro repeated cycles typically named biopanning or
phage display selections (Figure 1). This process includes
the following steps: (1) incubation: binding of the antibody
library repertoire to the antigen; (2) washing: elimination of
the nonspecific binders; and (3) elution and amplification:
obtaining antibodies binding to the antigen specifically for
further cycles or for screening. Although in the first cycle
of biopanning the whole antibody repertoire is exposed
to the antigen, depending on the fragment type of the
antibody and the phage display, 2–4 cycles of selections
are generally performed to enrich the specific binders.
Evaluation of the success of each cycle of the process and
enrichment is possible by comparing the phage titers after
elution steps against a blank that does not include antigen,
or alternatively it can be tested by ELISA (enzyme-linked
immunosorbent assay) (Hairul Bahara et al., 2013; Chan
et al., 2014; Ledsgaard et al., 2018; Teixeira and GonzalezPajuelo, 2018).
The most powerful advantages of phage display are
its small size and high diversity (antibody libraries up to
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Figure 1. Antibody display technologies. General schematic for in vitro and in vivo display techniques.

1011 clones), which allow to obtain antibody fragments
with the desired affinity and biophysical properties. Also,
this technique is preferred in both research areas and the
biopharmaceutical industry due to its library diversity,
ease of use, and low cost (Liu et al., 2017; Teixeira and
Gonzalez-Pajuelo, 2018). For example, belimumab (market
name Benlysta) was discovered and improved by phage
display and it is used to treat adults with active systemic
lupus erythematosus (Stohl and Hilbert, 2012). As a better
known example, adalimumab (market name Humira)
was discovered by phage display and it is widely used for
rheumatoid arthritis treatment (Bain and Brazil, 2003).
The number of antibodies discovered and/or optimized
by phage display has been exponentially increasing over
the last decade due to the many advantages listed above
(Nixon et al., 2014).
2.1.2. Ribosome and mRNA display
Ribosome and mRNA display techniques are cell-free and
this feature separates them from other display platforms.
They have high molecular diversity (antibody libraries
ranging from 1012 to 1014 clones) and enable isolation
of antibodies that show affinities at pM level. Both
techniques include the same basic features, such as in
vitro transcription and translation steps (Harel Inbar and
Benhar, 2012).
Ribosome-display technology was first reported in a
patent application in 1991. While the mRNA encoding
antibody library is translated in vitro, the translated

peptide and corresponding mRNA remain attached to
the ribosome (Figure 1). By this means, the peptide–
ribosome–mRNA (PRM) complex can be selected along
with the sequence information of the desired antibody
by affinity purification techniques. The most powerful
aspect of this technique is its large size of library, which
is not limited by the cell transformation efficiency. On
the other hand, the ribosome amount and the existence
of unrelated mRNA molecules are the main limitations of
this technique (Hanes and Pluckthun, 1997). Groves et al.
compared phage display and ribosome display to generate
scFvs to a specific antigen (Groves et al., 2014). They found
that scFvs affinity-matured by ribosome display had more
structural diversity in the HCDR3 and VH-VL interface
regions.
In the mRNA-display technique, first the antibody
DNA library is transcribed to mRNA. Then mRNA is
ligated to a linker, which is a DNA sequence linked to
puromycin. Thereafter, the mRNA-linker-puromycin
complex is translated. Puromycin first binds to the A-site
of the ribosome, then attacks the P-site and the nascent
peptide is transferred to puromycin, resulting in the
mRNA-linker-puromycin-antibody fragment complex.
The complex is then reverse-transcribed and the selection
process is performed. After the selection step, ss-DNA is
obtained by hydrolyzing the complementary mRNA via
high pH, and the desired DNA sequence is amplified by
PCR (Figure 1) (Sergeeva et al., 2006; Jijakli et al., 2016;

3

ARSLAN et al. / Turk J Biol
Liu et al., 2017). One of the limitations of this technique
is low efficiency of mRNA-protein conjugates. Nagumo
et al. overcame this problem by unexpected substitution
mutations around the start codon of antibodies (Nagumo
et al., 2016). These mutations destabilized the mRNA
secondary structure and this somehow led to a better
formation of conjugates and higher protein expression.
2.2. In vivo display technologies
2.2.1. Bacterial surface display
The bacterial surface display technique was developed as
a potential alternative to phage display (Sergeeva et al.,
2006). The use of bacteria as a display system was first
reported by George Georgiou’s group in 1993 (Georgiou
et al., 1993). They first used the Lpp-OmpA’ chimera to
display two specific scFvs on the outer membrane of the
gram-negative bacterium E. coli. Several years later, a new
approach was developed by the same group called APEx
(anchored periplasmic expression) (Jeong et al., 2007).
With this second system, scFvs were displayed in the
periplasmic space anchored to the inner membrane of E.
coli. For isolation of antigen-specific clones, flow cytometry
was used for both applications. Due to the technological
shortcoming of the FACS (fluorescence activated cell
sorting) of that time, library size was limited and thereby
this technique was basically used for the evolution of the
preexisting antibodies (Harel Inbar and Benhar, 2012). This
technique is more commonly used to display functional
enzymes, antigens, and especially polypeptide libraries (up
to 1011 library size) (Sergeeva et al., 2006; Liu et al., 2017).
For example, to identify peptide ligands specific for VEGF,
bacteria-displayed peptide libraries were constructed and
screened (Liu et al., 2017).
2.2.2. Yeast surface display
Yeast surface display was first demonstrated by Dane
Wittrup’s group using Saccharomyces cerevisiae to display
antibody repertoires (Harel Inbar and Benhar, 2012).
Yeast surface display is a powerful technique that allows
to obtain antibodies with desired affinity, specificity, and
stability. In this technique, scFvs that consist of VH and VL
regions and a polypeptide linker binding them together
are displayed. On yeast, scFvs are fused to the adhesion
subunit of the yeast agglutinin protein Aga2p, which is
bound to Aga1p via a disulfide bond and this complex
attaches the scFv to the yeast cell wall and finally the
desired antibody fragment is identified by FACS (Figure
1) (Feldhaus and Siegel, 2004; Chao et al., 2006; Liu et al.,
2017; Mei et al., 2017). This technique is commonly used
for antibody display and it has several advantages: (i) use
of FACS to monitor equilibrium activity statistics of the
sample; (ii) offering easy secretion and purification; and
(iii) using yeast cells, which can perform posttranslational
modification. On the other hand, it allows to display up to
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109 copies of scFv, which is a limitation as compared with
the other display platforms such as phage display (Chao
et al., 2006; Harel Inbar and Benhar, 2012). Also, the best
known disadvantage of yeast surface display is slower
growth rate and lower transformation efficiency compared
to both phage and bacteria surface display techniques (Mei
et al., 2017).
2.2.3. Mammalian surface display
Mammalian surface display was developed by Ira Pastan’s
group in 2006 (Ho et al., 2006). They used this technique
to display an scFv library fused to the N-terminal
transmembrane domain of human platelet-derived
growth factor receptor (PDGFR) on the surface of HEK293T cells and were able to isolate high-affinity anti-CD22
antibodies. Mammalian cell display has powerful aspects
for the isolation of scFv and whole IgG with high affinity
and other specific biological functions. For instance, they
can express mouse or human antibodies containing the
posttranslational modifications required for some key
antibody functions, and the technique can also be used to
express recombinant antibody fragments that cannot be
expressed in E. coli (Ho and Pastan, 2009). However, there
are only a few reports of the technique, basically due to
the limitation of repertoire size (ranging between 103 and
106). Similar to other techniques, it is required to transfer
genes encoding the desired proteins to proper host cells
by convenient vectors and to make sure that the desired
protein undergoes correct transcription and translation
processes. However, due to slower proliferation rates
of mammalian cells in contrast to microbial ones, it is
challenging to choose cells suitable for construction of
a convenient and rapid mammalian cell surface display
system. HEK-293, COS, and CHO cells are the most widely
used cell lines in mammalian surface display approaches.
HEK-293 has particularly been preferred more than others
because of its ease of transport, high yield, and native
human glycosylation (Qin and Li, 2014).
3. Rational design approaches
Aggregation, solubility, and stability are important
factors that affect the developability of an antibody. These
challenges can occur during the production process due to
the protein’s large complex profile and can cause reduced
antigen binding affinity, immunogenic responses, and
waste of resources. Aggregation/solubility and stability
properties of an antibody depend on both its sequence
and structure (Figure 2). It is advantageous to control
these properties with rational design before in vitro and in
vivo studies. Rational design methods aim to demonstrate
problematic regions of protein sequences or structures.
Thus, combining rational design methods and in vitro/in
vivo studies enhances the chance of antibodies with better
solubility and stability in the early production phase.
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Figure 2. Protein engineering approaches based on antibody regions. While solubility/
aggregation can be improved by engineering exposed residues, stability can be increased
by both exposed and core residues. Complementarity-determining regions (CDRs)
mainly affect specificity and affinity. Tags/linkers can be added for better functionality.

Intrinsic and extrinsic properties play important roles
in rational design predictions (Dubay et al., 2004; Pawar
et al., 2005). Physicochemical properties of amino acids
affect the antibody profile as intrinsic factors. For example,
the aggregation rate of the polypeptide can be increased
when the number of hydrophobic residues increases.
Also, extrinsic factors such as pH, ionic strength, and
temperature should be considered during sequence-based
prediction (Dubay et al., 2004). Both intrinsic and extrinsic
factors might change the properties and only aggregation/
solubility can be predicted based on the sequence because
the aggregation rate usually depends on amino acid
properties. On the other hand, stability and affinity depend
on both amino acid and structure properties.
Recent developments in rational design tools that
predict problematic regions of proteins help researchers
to improve antibody developability. Here, we introduce
rational design web tools that can be used to improve
aggregation/solubility, stability, and affinity properties
based on mutagenesis.
3.1. Aggregation/solubility
Protein aggregation is a common problem in therapeutic
antibodies and it can occur during production or storage.
On the molecular level, aggregation occurs due to specific
regions of a protein sequence named aggregation prone
regions (APRs) that determine its aggregation rate.

These APRs indicate specific charge, hydrophobicity, and
secondary structural properties and lead to aggregation
(Fink, 1998; Tartaglia and Vendruscolo, 2008; Agrawal et
al., 2011; Elgundi et al., 2017). Prediction of potential APRs
is the key function of aggregation/solubility prediction
tools.
Early studies showed that protein aggregation and
stability kinetics are computable and protein sequences
can be designed based on desired properties (Kamtekar
et al., 1993; West et al., 1999; Worn and Pluckthun, 1999;
Worn and Pluckthun, 2001). Several prediction tools have
been developed to determine the aggregation propensity of
a protein (Table). While most of them analyze the amyloid
formation, some analyze only aggregation propensity/
APRs. However, most of the tools can be used to analyze
antibody fragments due to their small size. The most
commonly used tools are Tango (Fernandez-Escamilla
et al., 2004), Waltz (Beerten et al., 2015), AggreScan
(Conchillo-Sole et al., 2007), Pasta 2.0 (Walsh et al., 2014),
and Camsol Instrinsic (Sormanni et al., 2015), which
determine the aggregation propensity of an antibody
based on its sequence.
Tango (http://tango.switchlab.org/) is the earliest
aggregation prediction tool and predicts the β-sheet
aggregation of a given protein sequence. It evaluates
probability scores for each amino acid’s beta turn, beta

5

6
Computes the position-specific scores to determine aggregation-prone regions
Gives output scores for each residue based on solubility profile of sequence

Waltz

Camsol Intrinsic

Identifies amyloidogenic regions in protein sequences
Focuses on effect of the mutations on intrinsic solubility profile of protein sequences
Determines the effect of amino acid variation on solubility profile
Gives graphical outputs of highlighted lysine arginine contents and solubility profile

Fısh Amyloid

Soda

Pon-Sol

Protein-Sol

Affinity

Stability

Aggregation/solubility

(Pandurangan et al., 2017)

Evaluates the stability differences between the wild type and mutated type protein
structure
Determines the structure and sequence-based stability changes depending on single
point mutation of protein

Uses amino acid–atom potential and torsion angle distribution information to identify
(Parthiban et al., 2006)
changes in protein stability-based on mutations

SDM

I-Mutant

Cupsat

Predicts antigen–antibody affinity changes upon mutations

(Wainreb et al., 2011)

Calculates protein stability based on differences between protein’s wild type and
mutated type free energies

ProMaya

mCSM-AB

Identifies the poorly soluble residues based on both position of amino acid and amino
(Zambrano et al., 2015)
acid structure

AggreScan3D

(Pires and Ascher, 2016)

(Capriotti et al., 2005)

Gives structurally corrected solubility profile to visualize poorly soluble regions on the
(Sormanni et al., 2015)
surface, determines the proper residues for mutation

Camsol Structurally
Corrected

(Hebditch et al., 2017)

(Yang et al., 2016)

(Paladin et al., 2017)

(Gasior and Kotulska, 2014)

Predicts aggregation-prone regions and estimates the effect of mutation on aggregation
(Conchillo-Sole et al., 2007)
profile

(Sormanni et al., 2015)

(Beerten et al., 2015)

AggreScan

Structure Based Prediction Web-Tools

Aggregation/Solubility

Evaluates the aggregation scores for each residue based on physicochemical principles (Fernandez-Escamilla et al., 2004)

Tango

(Walsh et al., 2014)

Predicts aggregation-prone, disordered regions

Pasta 2.0

References

Definition

Tool name

Sequence-based Prediction Web Tools

Table. Protein sequence and structure-based web tools for rational design approaches.
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sheet, alpha helix, and beta and alpha aggregation
considering given extrinsic conditions (pH, temperature,
ionic strength, concentration). The algorithm assumes
that specific regions of protein have high aggregation
propensity if they involve at least five consecutive residues
with a probability to populate the β-aggregate state higher
than 5% per residue. It was shown that Tango has a success
rate of 87% , correctly predicting 155 out of 179 peptides,
with 21 false positives and 3 false negatives (FernandezEscamilla et al., 2004).
Waltz (http://waltz.switchlab.org/) and Pasta 2.0 (http://
protein.bio.unipd.it/pasta2/) give highly aggregationprone/amyloid-forming regions as output. While Waltz
uses a position-specific scoring matrix (PSSM) with
physicochemical information to identify amyloid forming
regions (Beerten et al., 2015), Pasta 2.0 identifies amyloid
forming regions by calculating the pairing energies for
each pair of residues facing one another on parallel or
antiparallel neighboring strands within a β-sheet (Walsh
et al., 2014).
AggreScan and Camsol are listed in two subsections
of the Table because they can analyze protein aggregation
propensity based on both sequence and structure
information. Aggrescan (http://bioinf.uab.es/aggrescan/)
calculates aggregation propensity scores for each residue
in the sequence by averaging the aggregation propensity
score per residue over a given length (Conchillo-Sole et
al., 2007). Aggrescan3D (A3D) (http://biocomp.chem.
uw.edu.pl/A3D/) is an improved version of Aggrescan that
overcomes the limitations of sequence-based analyses.
A3D identifies aggregation prone residues, which are
related to folded states. Also, designed/desired mutation
effects on aggregation propensity of any protein can be
determined by using A3D (Zambrano et al., 2015).
The Camsol method can be used in two different
modes, ‘Camsol Intrinsic’ and ‘Camsol Structurally
Corrected’
(http://www-vendruscolo.ch.cam.ac.uk/
camsolmethod.html), to evaluate aggregation scores of any
protein. Camsol Intrinsic calculates the solubility profile
scores per amino acid by using the given protein sequence
and identifies the regions that are poorly soluble when
the score is smaller than –1. It evaluates the aggregation
propensity per residue using the sequence, charge,
hydrophobicity, and secondary structure propensity as
intrinsic factors. Camsol Structurally Corrected analyzes
the protein structure like Camsol Intrinsic but it shows the
poorly soluble regions on the surface that can be used to
identify suitable mutations to increase the solubility of the
protein. These poorly soluble regions can also be visualized
by using output structure (Sormanni et al., 2015, 2017).
These methods can be used separately or combined to
predict aggregation/solubility profiles and the combination
of different methods can provide higher accuracy for

mutagenesis studies. Van Der Kant et al. used only Tango
for prediction of APRs as a part of a study analyzing the
relationship between intrinsic aggregation propensity and
the local thermodynamic stability of over 2000 antibody
structures from the abYsis database (Van Der Kant et al.,
2017). Wang et al. combined Tango with structure-based
methods to predict APRs in antibody sequences based on
29 published Fab-antigen complexes (Wang et al., 2010).
They tested two different thresholds and they found that
Tango was more than 92% correct in their experimental
validation studies. In another study, estimations of Tango,
Aggrescan, and Pasta 2.0 were used to identify APRs that
were mostly confirmed by experimental results (Yageta et
al., 2015).
Lately several sequence-based aggregation propensity
prediction tools have also been developed. Gasior and
Kotulska proposed a classification method called Fish
Amyloid (http://comprec-lin.iiar.pwr.edu.pl/) that is able
to recognize amyloidogenic fragments based on welldefined patterns of residue distribution and cooccurrence
of position-specific amino acids in protein sequences
(Gasior and Kotulska, 2014). Fish Amyloid was trained on
different lengths of sequences and offered good potential for
prediction. PonSol (http://structure.bmc.lu.se/PON-Sol)
determines the effect of amino acid variations solubility
profiles. The tool uses 443 amino acid substitutions from 71
proteins and these amino acid substitutions are classified
as increasing, decreasing, and not affecting solubility (Yang
et al., 2016). Protein-Sol (https://protein-sol.manchester.
ac.uk/) is another recent sequence-based prediction tool
that uses datasets of Escherichia coli protein solubility for
comparison and calculates 35 sequence-based properties.
The tool gives graphical output of predicted solubility, fold
propensity, and net segment charge. Predicted solubility
scales from 0 to 1 and more than 0.45 solubility scores are
accepted as soluble. Also, lysine and arginine contents are
highlighted for modifying protein solubility (Hebditch et
al., 2017). Soda (http://protein.bio.unipd.it/soda/) predicts
the protein solubility changes based on calculations of
several physicochemical properties for given mutations.
The method compares the mutant type and wild type
profile properties and estimates the changes. Soda provides
convenience for different types of variations such as point
mutation, deletion, or insertion (Paladin et al., 2017).
As a case study, an scFv sequence used in our lab
was analyzed with some of the sequence-based tools
introduced above (Figure 3). The full scFv sequence
was given as input. As output, every residue had an
aggregation/solubility score based on the tool’s calculation
and they were highlighted as aggregation-prone according
to the tool’s corresponding thresholds. We determined
multiple regions of the scFv as aggregation-prone (at least
6 of 8 tools gave predicted aggregation-prone residues).
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Figure 3. A case study for web tools. Several tools introduced in this review were used to determine aggregation-prone regions of an
scFv sequence used in our lab. Blue highlighted regions are outputs of tools as aggregation prone regions. Each web tool has a different
threshold, which was not shown in this figure. Mutation site is selected according to common predicted regions of different tools (at least
6 of 8 tools gave same residues as aggregation-prone).

One of those regions is shown as an example in Figure 3.
Our future mutations will be focused on those regions to
improve the biophysical characteristics of our protein.
3.2. Stability
Protein stability can be predicted by calculating the change
in the Gibbs free energy due to substitution of an amino
acid and more negative values of free energy present
better stability (Thiltgen and Goldstein, 2012). Different
approaches can be used for prediction of protein stability,
such as physical, statistical, empirical, and/or machine
learning methods. While the first three approaches are
limited and are more time- and cost-intensive, machine
learning methods can quickly perform predictions based
on input mutation, protein sequence, and structural
information at the same time (Capriotti et al., 2004; Cheng
et al., 2006).
Several web-based tools were developed to predict
protein stability. ProMaya (http://bental.tau.ac.il/
ProMaya/) calculates the stability free energy change
upon mutations by combining a collaborative filteringbased algorithm (CF) and random forest regression.
The tool uses different available datasets of mutations in
the same and different positions. ProMaya suggests that
using known free energy values of mutations at a specific
position corrects the prediction of free energy differences
for other mutations (Wainreb et al., 2011).
SDM (http://marid.bioc.cam.ac.uk/sdm2) evaluates
the stability change between the wild type and mutant
protein by using a conformationally constrained
environment-specific substitution table (ESST). The
method analyzes the amino acid alteration with specific
structural parameters based on residue packing density
and the ESST. The webserver gives predicted stability
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difference scores interpreted as reduced, induced, or
unaffected stability (Pandurangan et al., 2017).
I-Mutant
(http://gpcr2.biocomp.unibo.it/cgi/
predictors/I-Mutant3.0/I-Mutant3.0.cgi) predicts protein
stability changes based on a support vector machine and
allows users to use protein structure or sequences for
prediction. It was shown that I-Mutant has an accuracy of
77%–80% for the dataset derived from ProTherm (Bava et
al., 2004; Capriotti et al., 2005).
Cupsat (http://cupsat.tu-bs.de/) uses atom potential
and torsion angle distribution information of amino
acids to identify protein stability free energy change upon
mutations. The tool analyzes the protein structure and
gives information about mutation site, solvent accessibility,
and torsion angle and whether the mutated amino acid has
suitable torsion angles or not. It was shown that Cupsat
achieved 80% prediction success for both thermal and
chemical stability (Parthiban et al., 2006).
3.3. Affinity/specificity
If affinity improvement is desired, in vitro/vivo methods
explained Section 2 of this review can be used. There
are many available affinity maturation strategies based
on directed evolution methods. Generally, mutations
in complementarity-determining regions (CDRs) for
improving antigen–antibody affinity cannot be predicted
by using rational design approaches because it is hard to
estimate the dynamic antigen–antibody complex structure.
However, there is a newly developed tool called mCSM-AB
(http://biosig.unimelb.edu.au/mcsm_ab/) that uses free
energy change upon mutation and estimates the affinity
change. In the tool, a negative sign means that the selected
mutation reduces affinity and a positive sign means that
the selected mutation increases affinity. It is important to

ARSLAN et al. / Turk J Biol
know that this tool allows users to select more than one
mutation (Pires and Ascher, 2016).
4. Discussion
The main aims of protein engineering approaches are
usually to improve affinity/specificity or to prevent
aggregation and increase solubility and stability while
not changing affinity/specificity. Although there are
some trade-offs during these processes, there are many
successful examples in the literature that improved the
biophysical characteristics of antibodies.
Enever et al. used a new approach called phage
display stress selection to screen for more stable human
nanobodies (Enever et al., 2015). Their goals were to
improve thermodynamic stability and to make nanobodies
resistant to aggregation. They generated error-prone PCR
phage libraries and subjected these libraries to various
stress conditions. Stress conditions were related to
temperature (incubation at 50–80 °C for various amounts
of time), pH (incubation at pH 3.2 for various amounts
of time), and protease (incubation with trypsin, elastase,
leucozyme). Selection results revealed that beneficial
mutations (both on CDRs and framework residues) were
common to most of the stress conditions. This means that
antibodies tend to mutate generic amino acids to improve
their biophysical properties.
Dudgeon et al. introduced a general strategy to
improve biophysical properties of antibody variable
domains (Dudgeon et al., 2012). They identified specific
positions in CDR regions (28, 30–33, 35 in VH and 24,
49–53, 56 in VL) and mutated those to aspartate or
glutamate. This strategy led to increased aggregation
resistance, which is advantageous for both diagnostic
and therapeutic applications. Although most of those
mutations were located in CDR regions, they showed that
binding performances were not significantly affected for
nearly half of the mutants.
Courtois et al. rationally designed a biobetter drug
candidate by mutating or engineering aggregation-prone
residues of a Fab fragment (Courtois et al., 2016). They
removed aggregation-prone residues by single point
mutations (hydrophobic residues to charged aspartate
or lysine) and found that stability increased up to 4-fold.
They also added a glycosylation site near aggregationprone regions to increase solubility and up to 3-fold
increases in stability were obtained. Most importantly,

these engineering approaches did not alter binding to the
target.
Before designing mutations to decrease aggregation
and/or increase stability of antibodies, three important
points should be considered carefully: (i) CDR regions of
the sequence should not be selected for mutation although
they have high predicted scores because they are usually
important for antigen binding and affinity/specificity
might be impaired. (ii) Exposed hydrophobic amino acids
are widely known to contribute to aggregation, and those
residues should be considered first for mutation. They are
preferentially mutated to hydrophilic, even charged amino
acids such as aspartate, glutamate (Dudgeon et al., 2012),
or lysine (Courtois et al., 2016) to circumvent aggregation
problems. (iii) Designed mutations should also be
compared with a natural repertoire because mutating
a residue to its naturally conserved amino acid might
improve its properties. The abYsis database is a web-based
tool that integrates sequence data from the European
Molecular Biology Laboratory European Nucleotide
Archive (EMBL-ENA) and structure data from the Protein
Data Bank (PDB). The abYsis database can be used to
determine location-specific amino acid distribution of the
natural repertoires of different organisms (Swindells et al.,
2017).
It is important to note that there could be some tradeoffs while improving the desired properties of an antibody
(solubility, stability, affinity). Thus, the designed change
should be considered for all properties. For example, while
a mutation increases the solubility, it might also decrease
stability at the same time. Affinity maturation can lead
to a better binder but this higher affinity antibody might
fail in the development phase due to its poor biophysical
characteristics. It is important to keep in mind that tradeoffs can occur while improving antibody fragments and
one should design their computational/experimental
setup accordingly.
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